THE WINDOW TO CHANGE

Roche

AGENDA

ROCHE-ASSOCIATED SCIENTIFIC PRESENTATIONS AT EURETINA 2024

THURSDAY, 19 SEPTEMBER

Roche Symposium Room 113/114 13:30–14:30	FARICIMAB ▼ **From clinical trials to RWD with faricimab: What you see is what you get**	**Khanani A, Grimaldi G, Koh A, Patel P**
Speakers' Corner 1 Speakers' Corner 11:05–11:10	PDS Characterisation of fibrosis in the Archway trial: The impact of continuous delivery of ranibizumab in patients with neovascular age-related macular degeneration	Chakravarthy U
Free Paper Session 8 Room 118/119 12:42–12:48	FARICIMAB Faricimab in DME: Results from the RHONE-X long-term extension trial	Schlottmann P
Free Paper Session 4 Room 118/119 15:12–15:18	FARICIMAB 12-month real-world clinical and anatomical outcomes with faricimab in patients with neovascular age-related macular degeneration: FARETINA-AMD	Lim J
Speakers' Corner 3 Speakers' Corner 15:30–15:35	FARICIMAB 12-month real-world clinical and anatomical outcomes with faricimab in patients with diabetic macular edema: The FARETINA-DME study	Sheth V

FRIDAY, 20 SEPTEMBER

Roche Symposium Room 115 09:45–10:45	FARICIMAB **The real world impact of faricimab on clinic capacity**	**Wong D, Hamilton R, Chhabra R, Ruiz-Medrano J**
Roche Symposium Room 211 13:45–14:45	FARICIMAB **Changing the nAMD game plan with faricimab – Dual pathway, drying and durability**	**Holz F, Lim J, Hamilton R, Koh A**
Roche Symposium Room 111 17:45–18:45	FARICIMAB **Changing the DME game plan with faricimab – Dual pathway, drying and durability**	**Schlottmann P, Pearce I, Vujosevic S, Udaondo P**
Free Paper Session 6 Room 118/119 09:00–09:06	FARICIMAB Impact of early intraretinal fluid reduction on one-year outcomes in diabetic macular edema	Lim J
Free Paper Session 6 Room 118/119 09:12–09:18	FARICIMAB Real-world treatment patterns and visual outcomes of faricimab use among eyes with diabetic macular edema (DME) in the United Kingdom: 1-year results from the FARWIDE-DME study	Peto T
Speakers' Corner 4 Speakers' Corner 09:15–09:20	PDS Port delivery system with ranibizumab for continuous treatment in diabetic retinopathy: 2-year data from the Phase 3 Pavilion trial	Khanani A
Free Paper Session 6 Room 118/119 09:18–09:24	FARICIMAB Visual acuity and anatomic improvements at Week 24 were maintained through Week 72 with faricimab treat-and-extend dosing in the Phase 3 BALATON and COMINO RVO trials: Patient case profiles and results summary	Dinah C
Free Paper Session 2 Room 118/119 11:00–11:06	FARICIMAB Analysis of extended interval treatment outcomes, potential for Q20W dosing and predictors of treatment durability in nAMD with faricimab from the TENAYA/LUCERNE trials	Koh A
Free Paper Session 2 Room 118/119 11:06–11:12	FARICIMAB Key clinical outcomes with faricimab in treatment-naïve patients with nAMD: Results from the TENAYA/LUCERNE trials and real-world FARETINA/FARWIDE studies	Souied E
Free Paper Session 2 Room 118/119 11:30–11:36	PDS Technical updates to port delivery system with ranibizumab (PDS) for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and diabetic retinopathy (DR)	Chang M
Free Paper Session 2 Room 118/119 11:54–12:00	PDS The clinical impact of continuous delivery of ranibizumab with the port delivery system in neovascular age-related macular degeneration	Zinkernagel M
EURETINA Session 6 Grand Auditorium 12:20–12:25	FARICIMAB Global real-world clinical and anatomical outcomes with faricimab in treatment-naïve patients with neovascular age-related macular degeneration or diabetic macular edema from a multi-country prospective non-interventional study: The VOYAGER study	Bailey C
Free Paper Session 7 Room 111 17:00–17:06	FARICIMAB Efficacy and safety of faricimab in ALTIMETER: A Phase 2b trial exploring biomarkers of angiopoietin-2 inhibition in patients with diabetic macular edema	Ziemssen F
Free Paper Session 7 Room 111 17:06–17:12	FARICIMAB Greater reduction in hard exudates with faricimab vs aflibercept in patients with DME: Biomarker results from the Phase 3 YOSEMITE/RHINE trials	Dinah C
Free Paper Session 7 Room 111 17:12–17:18	FARICIMAB Predictors of extended treatment intervals in patients with DME treated with faricimab in the Phase 3 YOSEMITE/RHINE trials	Ambresin A

SATURDAY, 21 SEPTEMBER

Roche Symposium Room 115 13:00–14:00	PDS **Is continuous drug delivery the key to transforming long-term outcomes in retinal diseases?**	**Figueroa M, Hillier R, Graff J, Chang M**
Speakers' Corner 10 Speakers' Corner 12:35–12:40	VAMIKIBART Advanced imaging biomarker assessment for SD-OCT and ultra-widefield fluorescein angiography using a machine-learning augmented analysis in patients with uveitic macular edema receiving vamikibart in the DOVETAIL study	Ehlers J
Free Paper Session 17 Room 118/119 16:06–16:12	VAMIKIBART IL-6 inhibition with vamikibart in patients with uveitic macular edema: Phase 3 MEERKAT and SANDCAT trials	Fonollosa A

VIRTUAL

Audio Narrated Free Paper Presentation	FARICIMAB Real-world treatment patterns and visual outcomes of faricimab use among eyes with neovascular age-related macular degeneration (nAMD) in the United Kingdom: 1 year results from the FARWIDE-nAMD study	McKibbin M
Audio Narrated Free Paper Presentation	FARICIMAB Assessment of the clinical effects of anti-Ang-2 with faricimab based on key outcomes from the YOSEMITE/RHINE trials and real-world FARETINA/FARWIDE studies in patients with DME	Finger R
Audio Narrated Free Paper Presentation	FARICIMAB Comparison of the relative effectiveness of faricimab vs aflibercept 8 mg in diabetic macular edema (DME)	Keane P
Audio Narrated Free Paper Presentation	FARICIMAB Early fluid resolution in the head-to-head phase of the TENAYA/LUCERNE trials is associated with short- and long-term extended durability in patients with neovascular age-related macular degeneration treated with faricimab	Gallego-Pinazo R
Audio Narrated Free Paper Presentation	FARICIMAB Reduction in pigment epithelial detachment (PED) with faricimab vs aflibercept: A subgroup analysis of patients with large and serous PEDs from the pooled Phase 3 TENAYA and LUCERNE trials	Khanani A
Audio Narrated Free Paper Presentation	PDS Patient preference for the port delivery system with ranibizumab (PDS) vs intravitreal injections: Results from the Phase 3 Pagoda trial in patients with diabetic macular edema (DME)	Chang M
Audio Narrated Free Paper Presentation	PDS Port delivery system with ranibizumab (PDS) for continuous treatment of diabetic macular edema (DME): 2-year data from the Phase 3 Pagoda trial	Graff J
Audio Narrated Free Paper Presentation	VAMIKIBART Intravitreal interleukin-6 inhibition with vamikibart in uveitic macular edema: Final results from the Phase 1 DOVETAIL study	Pavesio C
e-Poster	VAMIKIBART Relationship between aqueous humor interleukin-6 levels and disease characteristics in uveitic macular edema: The Phase 1 DOVETAIL study	Barekati Z
e-Poster	VAMIKIBART Vamikibart, an anti-IL-6 monoclonal anti-body, causes rapid and sustained intraocular suppression of IL-6 in patients with uveitic macular edema: Final PK/PD results from Phase 1 DOVETAIL study	Willen D

Please note that timings are subject to change by the EURETINA congress organisers. Please check the official programme for confirmation of timings.

Ang, angiopoietin; DME, diabetic macular edema; DR, diabetic retinopathy; HCP, healthcare professional; IL, interleukin; (n)AMD, (neovascular) age-related macular degeneration; PD, pharmacodynamic; PDS, Port Delivery System with ranibizumab; PED, pigment epithelial detachment; PK, pharmacokinetic; QxW, every x weeks; RVO, retinal vein occlusion; RWD, real-world data; SD-OCT, spectral domain-optical coherence tomography; UK, United Kingdom; US, United States of America.

This medical-scientific material contains information on therapies*,†,¶ that may have not yet been approved for use in your country, including by the European Commission, and for which no adequate statement on safety and efficacy can be made. This information does not intend to promote the use of products prior to or outside the respective marketing authorisation under drug law.

*Faricimab is approved for the treatment of neovascular age-related macular degeneration, diabetic macular edema and retinal vein occlusion in several countries worldwide, including by the European Commission. Approval conditions may vary internationally. Status as of September 2024. For details of prescribing information, please refer to the EU SmPC here. Ficha técnica disponible en el stand. The SmPC is available at the booth.

†The Port Delivery System with ranibizumab is approved for the treatment of neovascular age-related macular degeneration in the US. Port Delivery System con ranibizumab no está autorizado en Europa. Port Delivery System with ranibizumab is not authorized in Europe. Status as of September 2024.

¶Vamikibart is an investigational, non-authorized drug.

▼ Este medicamento está sujeto a seguimiento adicional, es prioritaria la notificación de sospechas de reacciones adversas asociadas a este medicamento.

▼ This medicinal product is subject to additional monitoring in EU countries. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Please report adverse reactions via the medinfo.roche.com website.

Following the Congress, you can access all Roche presentations, posters and symposia via the below websites.

For HCPs outside the UK, US, Canada, Australia and Spain only

Access to the Roche portal for Spanish HCPs only

M-XX-00018416 | Date of preparation September 2024